Skip to main content

Notice for Dupilumab (rch) (Sanofi-Aventis Australia Pty Ltd)

Active ingredients
Dupilumab (rch)
Date of review outcome
Lapse date
Type
Priority review
Indication
Dupilumab is indicated as an add-on maintenance treatment in adult patients with uncontrolled chronic obstructive pulmonary disease (COPD) associated with type 2 inflammation.
Therapeutic area
Respiratory

Help us improve the Therapeutic Goods Administration site